(MedPage Today) — Despite substantial health benefits, two GLP-1 receptor agonists weren’t cost-effective at their current prices, according to an economic evaluation that compared four anti-obesity medications. Net prices of tirzepatide (Mounjaro… Source link : https://www.medpagetoday.com/primarycare/obesity/114656 Author : Publish date : 2025-03-14 15:50:00 Copyright for syndicated content belongs to the linked Source.
The post High Price of GLP-1 Agents Tip Cost-Benefit Scale Unfavorably first appeared on News Health.
Author : News Health
Publish date : 2025-03-14 15:50:00
Copyright for syndicated content belongs to the linked Source.